ReviewJournal of blood medicine2023
Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives.
Review in Journal of blood medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Computational Fluid Dynamics Analysis of Cerebrovascular Hemodynamic Differences in Adults with Sickle Cell Disease: Comparing Stroke and Non-Stroke Cohorts.Annals of biomedical engineering · 2026Article
- Radiomic Features Extracted from Magnetic Resonance Imaging to Identify Arteriopathy in a Humanized Mouse Model of Sickle Cell Anemia and Sickle Cell Trait.Annals of biomedical engineering · 2026Article
- Spontaneous calvarial regeneration after craniectomy for sickle cell-related skull infarction and spontaneous epidural hematoma: implications for delayed cranioplasty.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Epidemiological and comorbidity burden in transfusion-dependent patients with thalassemia and sickle cell disease in Greece.Annals of hematology · 2026Observational
- Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.Blood advances · 2025Review
- Genetic and epigenetic architectures of stroke: Insights from GWAS to precision medicine.Neurochemistry international · 2025Review
- Article
- Clinical and Economic Burden of Managing Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Current understanding of stroke and stroke mimics in adolescents and young adults: a narrative review.International journal of emergency medicine · 2024Review
- Stroke Prevention and Treatment for Youth with Sickle Cell Anemia: Current Practice and Challenges and Promises for the Future.Current neurology and neuroscience reports · 2024Review
- Asymptomatic Maternal Diseases Presenting with Symptomatic Neonatal Manifestations: A Short Case Series.Children (Basel, Switzerland) · 2024Article
- Role of Traditional Stroke Risk Factors Aiding in Prediction of Infarcts in Adult Patients With Sickle Cell Disease.Journal of the American Heart Association · 2024Article
- Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke.Cureus · 2023Review
- From Stress to Sick(le) and Back Again-Oxidative/Antioxidant Mechanisms, Genetic Modulation, and Cerebrovascular Disease in Children with Sickle Cell Anemia.Antioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of protecting brain function for people with sickle cell disease (SCD) cannot be overstated. SCD is associated with multiple cerebrovascular complications that threaten neurocognitive function and life. Without screening and preventive management, 11% of children at 24% of adults with SCD have ischemic or hemorrhagic strokes. Stroke screening in children with SCD is well-established using transcranial Doppler ultrasound (TCD). TCD velocities above 200 cm/s significantly increase the risk of stroke, which can be prevented using chronic red blood cell (RBC) transfusion. RBC transfusion is also the cornerstone of acute stroke management and secondary stroke prevention. Chronic transfusion requires long-term management of complications like iron overload. Hydroxyurea can replace chronic transfusions for primary stroke prevention in a select group of patients or in populations where chronic transfusions are not feasible. Silent cerebral infarction (SCI) is even more common than stroke, affecting 39% of children and more than 50% of adults with SCD; management of SCI is individualized and includes careful neurocognitive evaluation. Hematopoietic stem cell transplant prevents cerebrovascular complications, despite the short- and long-term risks. Newer disease-modifying agents like voxelotor and crizanlizumab, as well as gene therapy, may treat cerebrovascular complications, but these approaches are investigational.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.